Another important anti-tumor mechanism of PARP inhibitors is “synthetic lethality.” In some breast and ovarian cancers with BRCA mutations, meaning the deficiency of the homologous recombination repair system (HR), BER driven by PARP functions as compensation. The gene discussed is PARP1; the disease is ovarian cancer.